度普利尤单抗治疗老年中重度特应性皮炎合并肾病综合征1例

Dupilumab for the Treatment of Elderly Moderate to Severe Atopic Dermatitis Patient Complicated with Nephrotic Syndrome:A Case Report

特应性皮炎(AD)是一种慢性复发性炎症性皮肤病,可影响患者的生活质量。度普利尤单抗是首个被批准用于治疗局部治疗效果不佳的中重度AD患者的生物制剂,其作用机制是阻断白细胞介素(IL)-4和IL-13信号转导。目前国外报道关于度普利尤单抗治疗伴有肾病的老年AD患者的病例很少,国内尚无报道。该病例提示对于患有肾病的老年AD患者,度普利尤单抗可以作为一种有效和安全的治疗,但仍需进一步研究证实。

Atopic dermatitis(AD)is a chronic recurrent inflammatory skin disease that can affect patients′quality of life.Dupilumab is the first biologic approved for the treatment of patients with moderate-to-severe AD who do not respond well to topical therapies by blocking interleukin(IL)-4 and IL-13 signaling.At present,there are few reported cases of dupilumab in the treatment of elderly AD patients with kidney disease abroad,and there are no reports in China.This case suggests that dupilumab can be used as an effective and safe treatment for elderly AD patients with kidney disease,but further studies are needed to confirm this.